Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 108

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 108
---
 the previous three years; (iii) the date on which we are deemed to be a large accelerated filer under the rules of the SEC;
or (iv) the last day of the fiscal year following the fifth anniversary of this offering. We may choose to take advantage of some
but not all of these exemptions. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage
of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting
standards. This means that an “emerging growth company” can delay the adoption of certain accounting standards until those
standards would otherwise apply to private companies. We have elected to take advantage of the extended transition period to comply with
new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies.
As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting
standards as other public companies that are not emerging growth companies which may make comparison of our financials to those of other
public companies more difficult.

Liquidity and Capital Resources

Since our inception, we
have incurred losses and negative cash flows from our operations. For the year ended December 31, 2024, we had an income of $4.8 million
(which was mainly due to the Horizon 2020 Grant and finance income from revaluation of our convertible motes and warrant liability) and
net cash of $0.6 million was used in our operating activities. For the six months ended June 30, 2025, we incurred a net loss of
$3.2 million and net cash of $ 0.34 million was used in our operating activities. As of June 30, 2025 and December 31,
2024, we had a negative working capital of $9.2 million and $6.0 million, respectively, and an accumulated deficit of approximately
$45.3 million and $42.1 million, respectively. As of September 29, 2025 and June 30, 2025, our cash and cash equivalents totaled
approximately $0.1 million and $0.2 million, respectively. Based on our current plans, we believe that our existing cash and cash
equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through October 2025
without giving effect to the proceeds